항균 펩타이드 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the antimicrobial peptides market size is expected to grow from USD 4.25 billion in 2025 to USD 4.58 billion in 2026 and is forecast to reach USD 6.66 billion by 2031 at 7.78% CAGR over 2026-2031.

This report is Segmented by Product Type (Plant, Bacterial, Animal, Insect), Source (Natural, Synthetic, Recombinant, Engineered), Application (Healthcare, Agriculture, Cosmetics, Others), Route (Topical, Oral, Injectables, Inhalation, Others), End Use (Pharmaceuticals, Biotechnology, Veterinary, Others), and Geography (North America, Europe, and More). Forecasts are Provided in Value (USD).

Global Antimicrobial Peptides Market Trends and Insights

Rising Antimicrobial Resistance and Multidrug-Resistant Pathogens

The antimicrobial peptides market is being pushed forward by the clear rise in resistant bacterial infections across both advanced and developing health systems. The October 2025 WHO warning showed widespread resistance to commonly used antibiotics, which has kept antimicrobial resistance at the center of treatment planning and stockpile decisions. The Lancet also projected 39.1 million deaths directly attributable to bacterial antimicrobial resistance between 2025 and 2050, which strengthens the urgency behind alternatives that work through different killing mechanisms. In the antimicrobial peptides market, that urgency matters because peptides disrupt bacterial membranes through multi-modal action rather than depending on one narrow target. Hospital buyers are therefore becoming more willing to review peptides earlier in the treatment pathway, especially where resistance has already made standard options less dependable. This is changing the commercial discussion from scientific interest alone to practical readiness for future procurement in resistant infection settings.

Expanding Use in Infection Prevention, Wound Care, and Device Coatings

The antimicrobial peptides market is also expanding through applications that do not rely on full systemic drug adoption. Device coatings and topical wound care use peptides at the site of infection risk, which lowers exposure concerns and makes the value proposition easier for many buyers to assess. A 2025 Phase 1 study of TCP-25 in wounds linked to dystrophic epidermolysis bullosa reported safety, tolerability, and possible support for wound healing, which gave the field a useful clinical proof point for topical peptide bioactives. That result supports a broader commercial pattern in which device makers and wound care suppliers can evaluate peptide formulations before broad therapeutic approvals become available. The antimicrobial peptides market benefits from this path because revenue can begin building through localized and specialty uses while larger systemic programs are still maturing. This gives mid-sized manufacturers a reason to plan custom synthesis and formulation capacity ahead of broader hospital uptake.

Proteolytic Instability and Short In Vivo Half-Life

The antimicrobial peptides market still faces a major constraint from the rapid degradation of many natural peptide sequences in vivo. Unmodified linear peptides can be cleaved quickly by common proteases, which makes systemic and oral delivery much harder than the biological activity alone might suggest. Developers are responding with D-amino acid substitution, fluorination, cyclization, and nanocarrier approaches, but each step adds manufacturing burden and formulation complexity. A 2025 Journal of Medicinal Chemistry study showed that the fluorinated analogue FuK achieved a serum half-life above 1,440 minutes compared with fewer than 225 minutes for the parent peptide. Even with that gain, the antimicrobial peptides market still has to absorb the cost of more advanced synthesis workflows before many systemic products can compete comfortably on price and scale. This keeps the best commercial positioning with companies that own delivery know-how rather than with producers that only offer standard peptide synthesis.

Other drivers and restraints analyzed in the detailed report include:

1. AI-Guided Peptide Design and Next-Gen Delivery Systems Improving Developability
2. Translational Funding for Anti-Infective and Peptide Platforms
3. High Cost of Solid-Phase Synthesis and Purification

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Plant Antimicrobial Peptides held 48.31% of the antimicrobial peptides market share in 2025, which made them the largest product type in the antimicrobial peptides market. Their lead reflects the commercial familiarity of defensins and thionins across pharmaceutical, agricultural, and food-related uses. The same segment is also forecast to expand at 8.38% CAGR through 2031, which shows that plant-derived formats are still gaining ground rather than simply defending a mature base. Plant peptides benefit from wide proteomic diversity and from the lower extraction burden that can be achieved with high-biomass crops such as soybean, wheat, and potato. That combination keeps them attractive for buyers that need functional efficacy without taking on the cost and design complexity of more engineered peptide classes.

The antimicrobial peptides market continues to treat plant-derived options as the most practical entry point for non-therapeutic formulations because they fit clean-label and compliance-driven purchasing behavior in several end uses. In Europe, demand is reinforced by food-contact and personal care requirements that favor ingredients backed by clear compliance documentation, and this supports continued demand for well-characterized plant peptide lots. In Asia-Pacific, suppliers with regulatory readiness are also positioned to move earlier in food-safety and specialty ingredient channels, which helps explain why plant sequences remain central to regional commercial planning. Bacterial antimicrobial peptides are gaining visibility in probiotics and microbiome-directed products, while animal-derived peptides, especially cathelicidin-linked formats, are drawing attention in wound-care development programs. Insect-derived peptides remain smaller in revenue terms, yet they are being watched for crop-protection use because one active can potentially cover both insecticidal and antibacterial roles, which gives them a practical formulation advantage.

Natural Sources held 38.44% share in 2025, which kept them in the leading source position within the antimicrobial peptides market. That lead came from established extraction methods and from the cleaner product perception that natural materials still hold in cosmetics, functional food, and some specialty care uses. Even so, Synthetic Peptides are forecast to record the highest CAGR at 8.52% through 2031, which makes source competition one of the clearest structural shifts in the antimicrobial peptides market. Synthetic formats are gaining because they allow tighter control over sequence design, purity, and batch reproducibility when activity needs to be tuned against defined resistant strains. This is especially important as discovery programs move away from broad exploratory libraries and toward more deliberate sequence engineering.

The antimicrobial peptides industry is therefore becoming more dependent on synthesis quality and design precision than on raw biological origin alone. Recombinant peptides are also expanding where fermentation can offer a workable cost profile for selected sequences, especially in biotechnology-led settings that can absorb process development with a longer view. Engineered peptides remain the highest-value source class on a unit basis because they include D-amino acids, stapled structures, or unnatural residues that are often aimed at difficult systemic indications. The antimicrobial peptides market is also seeing a narrower cost gap between natural and synthetic approaches because added SPPS capacity in India, Spain, and Sweden has made mid-scale commercial synthesis more competitive than it had been in earlier years. That narrowing does not remove the scale advantage of natural materials, but it does improve the commercial position of synthetic programs that need repeatable design and cleaner optimization loops.

Complete Report Scope:

• By Product Type
  • Plant Antimicrobial Peptides
  • Bacterial Antimicrobial Peptides
  • Animal Antimicrobial Peptides
  • Insect Antimicrobial Peptides
• By Source
  • Natural Sources
  • Synthetic Peptides
  • Recombinant Peptides
  • Engineered Peptides
• By Application
  • Healthcare and Therapeutics
  • Agriculture and Animal Health
  • Cosmetics and Personal Care
  • Other Applications
• By Route of Administration
  • Topical
  • Oral
  • Injectables
  • Inhalation
  • Other Routes of Administration
• By End Use
  • Pharmaceuticals
  • Biotechnology
  • Veterinary Clinics
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 38.61% of the antimicrobial peptides market share in 2025, which kept it in the leading regional position. The region benefits from the United States' strength in clinical pipeline activity, peptide manufacturing relationships, and public support for anti-infective development. BARDA's cumulative investment of more than USD 2.7 billion in antimicrobial products continues to signal policy-level commitment, and that backing has helped move peptide programs closer to viable commercial pathways. Canada and Mexico contribute through research collaboration and manufacturing services, yet the United States remains the main revenue anchor in the antimicrobial peptides market. North American demand is also encouraging long-term supply planning with overseas manufacturers, which means regional consumption strength does not always translate into the same level of local manufacturing share.

Europe held the second-largest regional position in the antimicrobial peptides market, with Germany and the United Kingdom standing out for pharmaceutical-grade peptide work and deep scientific infrastructure. A November 2024 research announcement tied to the German Research Foundation highlighted continued work on the antimicrobial selectivity of lugdunin through collaboration between Friedrich-Alexander University Erlangen-Nurnberg and the University of Gottingen. In Germany, the economic burden of multidrug-resistant nosocomial infections reached EUR 1.1 billion (USD 1.26 billion) in 2025, which is making the cost of resistance a more direct procurement argument inside hospitals. Europe also supports non-therapeutic demand in the antimicrobial peptides market because buyers in food-contact and personal care applications place value on traceability, compliance, and documentation quality.

Asia-Pacific is forecast to grow at 8.65% CAGR through 2031, which makes it the fastest-growing regional block in the antimicrobial peptides market. China is building around synthetic peptide innovation and agricultural applications, while Japan continues to contribute through high-grade manufacturing and ongoing participation in anti-infective funding networks. India is adding SPPS capacity through a broader peptide manufacturing buildout, and that capacity can support antimicrobial peptide programs as order patterns diversify. The antimicrobial peptides market is also gaining from the region's ability to combine lower-cost production expansion with strong local demand for advanced bioactive ingredients. Middle East and Africa, along with South America, still represent smaller shares, yet the resistance burden across several low- and middle-income settings creates a long-run need base that is structurally important for the antimicrobial peptides market.

1. Abzena
2. AMP Biotech
3. AnaSpec, Inc.
4. Bachem Holding
5. Bio-Techne
6. Creative Peptides
7. Genscript
8. JPT Peptide Technologies GmbH
9. Lonza Group
10. Merck
11. Novozymes A/S
12. PeptiDream Inc.
13. Phoenix Biotechnology, Inc.
14. PolyPeptide Group
15. Synpeptide Co., Ltd.
16. Thermo Fisher Scientific
17. WuXi App Tec

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Antimicrobial Resistance and Multidrug-Resistant Pathogens
  • 4.2.2 Expanding Use in Infection Prevention, Wound Care, and Device Coatings
  • 4.2.3 Higher Success Potential of Engineered Peptides Versus Conventional Small-Molecule Antibiotics
  • 4.2.4 AI-Guided Peptide Design and Next-Gen Delivery Systems Improving Developability
  • 4.2.5 Rising Demand for Non-Antibiotic Bioactives in Cosmetics, Food Preservation, and Veterinary Use
  • 4.2.6 Translational Funding for Anti-Infective and Peptide Platforms
• 4.3 Market Restraints
  • 4.3.1 Proteolytic Instability and Short In Vivo Half-Life
  • 4.3.2 High Cost of Solid-Phase Synthesis and Purification
  • 4.3.3 Narrow Therapeutic Window and Cytotoxicity Risk
  • 4.3.4 Weak Commercial Pull From Conservative Hospital Procurement and Reimbursement Scrutiny
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Plant Antimicrobial Peptides
  • 5.1.2 Bacterial Antimicrobial Peptides
  • 5.1.3 Animal Antimicrobial Peptides
  • 5.1.4 Insect Antimicrobial Peptides
• 5.2 By Source
  • 5.2.1 Natural Sources
  • 5.2.2 Synthetic Peptides
  • 5.2.3 Recombinant Peptides
  • 5.2.4 Engineered Peptides
• 5.3 By Application
  • 5.3.1 Healthcare and Therapeutics
  • 5.3.2 Agriculture and Animal Health
  • 5.3.3 Cosmetics and Personal Care
  • 5.3.4 Other Applications
• 5.4 By Route of Administration
  • 5.4.1 Topical
  • 5.4.2 Oral
  • 5.4.3 Injectables
  • 5.4.4 Inhalation
  • 5.4.5 Other Routes of Administration
• 5.5 By End Use
  • 5.5.1 Pharmaceuticals
  • 5.5.2 Biotechnology
  • 5.5.3 Veterinary Clinics
  • 5.5.4 Others
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Abzena
  • 6.3.2 AMP Biotech
  • 6.3.3 AnaSpec, Inc.
  • 6.3.4 Bachem Holding AG
  • 6.3.5 Bio-Techne Corporation
  • 6.3.6 Creative Peptides
  • 6.3.7 GenScript Biotech Corporation
  • 6.3.8 JPT Peptide Technologies GmbH
  • 6.3.9 Lonza Group AG
  • 6.3.10 Merck KGaA
  • 6.3.11 Novozymes A/S
  • 6.3.12 PeptiDream Inc.
  • 6.3.13 Phoenix Biotechnology, Inc.
  • 6.3.14 PolyPeptide Group
  • 6.3.15 Synpeptide Co., Ltd.
  • 6.3.16 Thermo Fisher Scientific Inc.
  • 6.3.17 WuXi AppTec

7 Market Opportunities and Future Outlook

• 7.1 White-Space and Unmet-Need Assessment